spacer
home > pmps > spring 2019 > a safer journey
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Safer Journey

In the last five years, more than 1,000 clinical trials have used cell and gene therapies. Furthermore, over 500 cell and gene therapy candidates are being actively researched (1). Indeed, the 2017 approval of two autologous CAR T therapies has clearly shown that for treatments like this to expand, the paramount logistical support has to evolve rapidly.

The cell and gene therapy sector, which could deliver life-changing treatments for some of the world’s most severe conditions and diseases, relies upon a logistical supply chain that must perform to high clinical standards.

Often, cell and gene therapies also require high harvesting of patient tissue that must then be transported to the manufacturing facility, with the resulting product returned to the patient’s clinicians. As the patient is an integral component of the supply chain, the logistical support provided must be robust and secure. Any breakdown or erosion in the efficiency of the supply chain could have massive consequences for patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christopher Good holds a BSc in chemistry and chemical technology and has worked for Biocair, a specialist logistics provider dedicated to the pharmaceutical, biotechnology, and life sciences sector, for 17 years. During this time, he has worked with many large multinational clients, developing and delivering innovative solutions to their global specialist logistical needs. These include the design and implementation of bespoke packaging, as well as building and managing complex global supply chains. Based in Cambridge, UK, Christopher continues to work closely with clients and colleagues alike to develop and provide best in class solutions and services in complex areas such as the provision of cell and gene therapy logistics.
spacer
Christopher Good
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Using Device Strategy to Drive R&D Productivity

Phillips-Medisize


More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement